JP2006514021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514021A5 JP2006514021A5 JP2004559442A JP2004559442A JP2006514021A5 JP 2006514021 A5 JP2006514021 A5 JP 2006514021A5 JP 2004559442 A JP2004559442 A JP 2004559442A JP 2004559442 A JP2004559442 A JP 2004559442A JP 2006514021 A5 JP2006514021 A5 JP 2006514021A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cell
- compound
- mediated
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 5
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 claims 4
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 101150069380 JAK3 gene Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000006470 autoimmune attack Effects 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43185102P | 2002-12-09 | 2002-12-09 | |
| PCT/US2003/038993 WO2004052359A1 (en) | 2002-12-09 | 2003-12-09 | Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514021A JP2006514021A (ja) | 2006-04-27 |
| JP2006514021A5 true JP2006514021A5 (https=) | 2006-12-07 |
Family
ID=32507812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559442A Pending JP2006514021A (ja) | 2002-12-09 | 2003-12-09 | Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7365096B2 (https=) |
| EP (1) | EP1578411A4 (https=) |
| JP (1) | JP2006514021A (https=) |
| KR (1) | KR20050084224A (https=) |
| CN (1) | CN1747729A (https=) |
| AU (1) | AU2003297740B2 (https=) |
| BR (1) | BR0317099A (https=) |
| CA (1) | CA2506432A1 (https=) |
| EC (1) | ECSP055843A (https=) |
| HU (1) | HUP0500844A2 (https=) |
| MX (1) | MXPA05006133A (https=) |
| NO (1) | NO20052497L (https=) |
| NZ (1) | NZ540427A (https=) |
| PL (1) | PL376844A1 (https=) |
| RU (1) | RU2005121672A (https=) |
| WO (1) | WO2004052359A1 (https=) |
| ZA (1) | ZA200504163B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7943800B2 (en) | 2003-03-28 | 2011-05-17 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| AU2005237254B2 (en) * | 2004-05-03 | 2010-02-04 | Novartis Ag | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| JP5149001B2 (ja) | 2004-05-25 | 2013-02-20 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の処置におけるマイグラスタチンアナログ |
| US8188141B2 (en) | 2004-09-23 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
| PL1940465T3 (pl) | 2005-10-26 | 2013-01-31 | Novartis Ag | Nowe zastosowanie przeciwciał anty-IL-1beta |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| CN104873972A (zh) | 2007-05-29 | 2015-09-02 | 诺华股份有限公司 | 抗IL-1β治疗的新适应症 |
| JP2011515068A (ja) | 2007-11-08 | 2011-05-19 | ノバルティス アーゲー | 慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| WO2011006119A2 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| US9018006B2 (en) | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| KR20140025530A (ko) | 2011-06-27 | 2014-03-04 | 노파르티스 아게 | 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염 |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| CN103987699A (zh) | 2011-10-21 | 2014-08-13 | 诺华股份有限公司 | 作为pi3k调节剂的喹唑啉衍生物 |
| US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| EP2790705B1 (en) | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| WO2013148638A2 (en) * | 2012-03-26 | 2013-10-03 | Ep Pharma, Inc. | Compositions and methods related to inhibitors of jak kinase |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015179773A1 (en) | 2014-05-22 | 2015-11-26 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| CN104090115B (zh) * | 2014-07-10 | 2016-01-13 | 上海益诺思生物技术有限公司 | 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法 |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| CN113840821A (zh) | 2019-05-23 | 2021-12-24 | 诺华股份有限公司 | Btk抑制剂的晶型 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA712187A (en) * | 1965-06-22 | J. C. Buisson Paul | 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same | |
| FR1466205A (fr) * | 1960-04-01 | 1967-01-20 | Chimie Atomistique | Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation |
| AU566673B2 (en) | 1983-09-15 | 1987-10-29 | F. Hoffmann-La Roche Ag | Phenethylamine derivatives |
| US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| KR20010089171A (ko) | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| CA2392554A1 (en) * | 1999-11-30 | 2001-06-28 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| CA2326952A1 (en) | 2000-11-27 | 2002-05-27 | The Hospital For Sick Children | T cell protein tyrosine phosphatase |
-
2003
- 2003-12-09 CA CA002506432A patent/CA2506432A1/en not_active Abandoned
- 2003-12-09 HU HU0500844A patent/HUP0500844A2/hu unknown
- 2003-12-09 EP EP03796805A patent/EP1578411A4/en not_active Withdrawn
- 2003-12-09 US US10/731,769 patent/US7365096B2/en not_active Expired - Fee Related
- 2003-12-09 CN CNA2003801054687A patent/CN1747729A/zh active Pending
- 2003-12-09 JP JP2004559442A patent/JP2006514021A/ja active Pending
- 2003-12-09 BR BR0317099-3A patent/BR0317099A/pt not_active IP Right Cessation
- 2003-12-09 KR KR1020057010469A patent/KR20050084224A/ko not_active Ceased
- 2003-12-09 NZ NZ540427A patent/NZ540427A/en unknown
- 2003-12-09 AU AU2003297740A patent/AU2003297740B2/en not_active Ceased
- 2003-12-09 MX MXPA05006133A patent/MXPA05006133A/es unknown
- 2003-12-09 WO PCT/US2003/038993 patent/WO2004052359A1/en not_active Ceased
- 2003-12-09 RU RU2005121672/15A patent/RU2005121672A/ru not_active Application Discontinuation
- 2003-12-09 PL PL376844A patent/PL376844A1/pl not_active Application Discontinuation
-
2005
- 2005-05-23 ZA ZA200504163A patent/ZA200504163B/en unknown
- 2005-05-24 NO NO20052497A patent/NO20052497L/no not_active Application Discontinuation
- 2005-06-08 EC EC2005005843A patent/ECSP055843A/es unknown
-
2007
- 2007-11-05 US US11/935,147 patent/US7928062B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514021A5 (https=) | ||
| ES2210339T3 (es) | Medicamentos para el tratamiento de cardiopatias inflamatorias. | |
| JPH1180026A (ja) | 新規免疫抑制剤、その使用方法およびその同定方法 | |
| RU2005121672A (ru) | Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего | |
| RU2004133347A (ru) | Лекарственное средство для профилактики и/или лечения хронического отторжения | |
| AU2005249231A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| JPH08512048A (ja) | 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物 | |
| JP6129155B2 (ja) | 同種移植片拒絶反応を抑制する方法 | |
| EP1932522B1 (en) | Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient | |
| RU2014837C1 (ru) | Средство для лечения панкреатита и предупреждения отторжения трансплантата поджелудочной железы и способ предупреждения отторжения трансплантата поджелудочной железы | |
| Markovic et al. | Anesthesia inhibits interferon-induced natural killer cell cytotoxicity via induction of CD8+ suppressor cells | |
| Waegell et al. | A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection | |
| JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
| Yanagawa et al. | The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival | |
| US6355639B1 (en) | Reverse prenyl compounds as immunosuppressants | |
| US20210069199A1 (en) | Methods of treating transplant rejection | |
| JP2000501118A (ja) | ２，２′−ビ−１ｈ−ピロール化合物を含有する相乗作用性免疫抑制剤組成物 | |
| US5521185A (en) | Methods for inhibiting graft rejection and IL-1 production | |
| CA2279214A1 (en) | Antiviral agents | |
| EP1032401B1 (fr) | Procede d'inhibition de la production cellulaire de cytokines | |
| HUP0300686A2 (hu) | Szívtranszplantátumok kilökődésének kezelésére szolgáló gyógyszerkészítmény, mely nem-peptid CCR1 receptor antagonista és ciklosporin A kombinációját tartalmazza | |
| NL8700191A (nl) | Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen. | |
| KR100324302B1 (ko) | 콜키친, 또는 콜키친 및 클로로카인을 유효성분으로서함유하는 면역억제제 | |
| Edwards et al. | Effects of a selective nitric oxide sythase-2 inhibitor in the prevention of acute cardiac allograft rejection | |
| Fingerhut et al. | 3 Deazaadenosin prevents leukocyte evasion by suppression of adhesion molecule expression during acute cardiac allograft rejection |